MedTrace Logo

Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

NCT07229157 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2026-01-23

No results posted yet for this study

Summary

The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in participants living with overweight or obesity.

Conditions

Interventions

DRUG

Maridebart Cafraglutide

Participants will receive maridebart cafraglutide SC.

DRUG

Moxifloxacin

Participants will receive moxifloxacin orally.

DRUG

Placebo for Maridebart Cafraglutide

Participants will receive placebo for maridebart cafraglutide SC.

DRUG

Placebo for Moxifloxacin

Participants will receive placebo for moxifloxacin orally.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-22
Primary Completion
2026-08-26
Completion
2026-08-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07229157 on ClinicalTrials.gov